J. Cheng

643 total citations
27 papers, 504 citations indexed

About

J. Cheng is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology. According to data from OpenAlex, J. Cheng has authored 27 papers receiving a total of 504 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 7 papers in Otorhinolaryngology. Recurrent topics in J. Cheng's work include Cancer Immunotherapy and Biomarkers (11 papers), Head and Neck Cancer Studies (7 papers) and Peptidase Inhibition and Analysis (4 papers). J. Cheng is often cited by papers focused on Cancer Immunotherapy and Biomarkers (11 papers), Head and Neck Cancer Studies (7 papers) and Peptidase Inhibition and Analysis (4 papers). J. Cheng collaborates with scholars based in United States, Spain and Canada. J. Cheng's co-authors include Raanan Berger, Bruce A. Werness, James S. Babb, N J Meropol, Kenneth Emancipator, Kumudu Pathiraja, Marisa Dolled‐Filhart, Edward J. Gonzalez, Tamara Rordorf and Shilpa Gupta and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

J. Cheng

27 papers receiving 497 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. Cheng United States 12 331 150 148 97 88 27 504
Nhu Le Canada 6 132 0.4× 87 0.6× 175 1.2× 92 0.9× 29 0.3× 7 372
Willa Shi Canada 7 238 0.7× 200 1.3× 113 0.8× 138 1.4× 50 0.6× 7 563
Cyril Abdeddaim France 10 302 0.9× 77 0.5× 92 0.6× 86 0.9× 66 0.8× 30 519
Yu Ohkubo Japan 10 177 0.5× 65 0.4× 120 0.8× 141 1.5× 148 1.7× 25 494
Zijun Zhen China 12 155 0.5× 103 0.7× 60 0.4× 47 0.5× 74 0.8× 62 389
François Casteillo France 11 204 0.6× 62 0.4× 197 1.3× 71 0.7× 58 0.7× 30 366
Ajit Paintal United States 12 99 0.3× 91 0.6× 128 0.9× 65 0.7× 31 0.4× 24 333
Hari A. Deshpande United States 10 136 0.4× 120 0.8× 90 0.6× 57 0.6× 16 0.2× 46 363
Christian Lussier Canada 10 122 0.4× 206 1.4× 45 0.3× 96 1.0× 27 0.3× 16 408
Paloma Martín-Martorell Spain 11 279 0.8× 82 0.5× 190 1.3× 37 0.4× 35 0.4× 30 426

Countries citing papers authored by J. Cheng

Since Specialization
Citations

This map shows the geographic impact of J. Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Cheng more than expected).

Fields of papers citing papers by J. Cheng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Cheng. The network helps show where J. Cheng may publish in the future.

Co-authorship network of co-authors of J. Cheng

This figure shows the co-authorship network connecting the top 25 collaborators of J. Cheng. A scholar is included among the top collaborators of J. Cheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Cheng. J. Cheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Burtness, Barbara, Kevin J. Harrington, Richard Greil, et al.. (2018). KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Annals of Oncology. 29. viii729–viii729. 97 indexed citations
2.
Steiniche, Torben, Jesper Grau Eriksen, Michael Busch-Sørensen, et al.. (2018). Programmed death-ligand 1 (PD-L1) expression and HPV-associated p16 in oropharyngeal squamous cell carcinoma (OSCC) treated with primary curative radiotherapy (RT). Annals of Oncology. 29. viii386–viii386. 1 indexed citations
3.
Tourneau, Christophe Le, Ezra E.W. Cohen, Kevin J. Harrington, et al.. (2018). Pembrolizumab for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of treatment options from the phase III KEYNOTE-040 trial. Annals of Oncology. 29. viii373–viii374. 5 indexed citations
4.
5.
Haddad, Robert I., Tanguy Y. Seiwert, David G. Pfister, et al.. (2016). Pembrolizumab after progression on platinum and cetuximab in head and neck squamous cell carcinoma (HNSCC): results from KEYNOTE-055. Annals of Oncology. 27. vi330–vi330. 11 indexed citations
6.
Hsu, Chih‐Hung, Seung‐Hoon Lee, Samuel Ejadi, et al.. (2015). 315O_PR Antitumor activity and safety of pembrolizumab in patients with PD-L1-positive nasopharyngeal carcinoma: Interim results from a phase 1b study. Annals of Oncology. 26. ix93–ix93. 13 indexed citations
7.
Kao, Hsiang‐Fong, et al.. (2015). Correlation between plasma EBV DNA and clinical response to pembrolizumab in patients with advanced or metastatic nasopharyngeal carcinoma. Annals of Oncology. 26. viii5–viii5. 1 indexed citations
8.
Chung, Hyun Cheol, Veena Shankaran, Ravit Geva, et al.. (2015). LBA-04 Clinical outcomes and their correlation with gene expression in patients with advanced gastric cancer treated with pembrolizumab (MK-3475): KEYNOTE-012. Annals of Oncology. 26. iv118–iv118. 5 indexed citations
9.
Gupta, Supriya, Antoine Hollebecque, Guillem Argilés, et al.. (2014). Safety and Efficacy of MK-8669 (Ridaforolimus) + MK-2206 (AKT Inhibitor) in Patients with Advanced Breast Cancer with PI3K Pathway Dependence. Annals of Oncology. 25. i25–i25. 1 indexed citations
10.
11.
Plimack, Elizabeth R., Shilpa Gupta, Joaquim Bellmunt, et al.. (2014). A Phase 1B Study of Pembrolizumab (Pembro; Mk-3475) in Patients (Pts) with Advanced Urothelial Tract Cancer. Annals of Oncology. 25. v1–v1. 41 indexed citations
12.
Chow, Laura Q.M., Barbara Burtness, Jared Weiss, et al.. (2014). A Phase Ib Study of Pembrolizumab (Pembro; Mk-3475) in Patients (Pts) with Human Papiilloma Virus (Hpv)-Positive and Negative Head and Neck Cancer (Hnc). Annals of Oncology. 25. v1–v1. 19 indexed citations
13.
Muro, Kei, Yung‐Jue Bang, Veena Shankaran, et al.. (2014). A Phase 1B Study of Pembrolizumab (Pembro; Mk-3475) in Patients (Pts) with Advanced Gastric Cancer. Annals of Oncology. 25. v1–v1. 48 indexed citations
14.
Oza, Amit M., A. Poveda, Sandro Pignata, et al.. (2011). A randomized phase II (RP2) trial of ridaforolimus (R) compared with progestin (P) or chemotheraphy (C) in female adult patients with advanced endometrial carcinoma.. Journal of Clinical Oncology. 29(15_suppl). 5009–5009. 25 indexed citations
15.
Leijen, Suzanne, Jan H.M. Schellens, Geoffrey I. Shapiro, et al.. (2010). A phase I pharmacological and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.. Journal of Clinical Oncology. 28(15_suppl). 3067–3067. 28 indexed citations
16.
Mehren, Margaret von, Russell J. Schilder, J. Cheng, et al.. (2008). A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies. Annals of Oncology. 19(10). 1802–1809. 41 indexed citations
17.
Konski, André, Steven J. Cohen, J. Cheng, et al.. (2008). The Effect of Gender and Dose on the Development of Symptomatic Cardiac Toxicity after Chemoradiotherapy for Esophageal Carcinoma. International Journal of Radiation Oncology*Biology*Physics. 72(1). S254–S254. 1 indexed citations
18.
Astsaturov, Igor, Neal J. Meropol, R. Katherine Alpaugh, et al.. (2007). A randomized phase II and coagulation study of bevacizumab alone or with docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma. Journal of Clinical Oncology. 25(18_suppl). 4556–4556. 9 indexed citations
19.
Garden, Adam S., Jonathan Harris, A. Trotti, et al.. (2005). Concomitant Boost Radiation and Concurrent Cisplatin for Advanced Head and Neck Carcinomas: Update of a Phase II Trial of the RTOG (99-14). International Journal of Radiation Oncology*Biology*Physics. 63. S71–S72. 2 indexed citations
20.
Cohen, Steven J., Neal J. Meropol, André Rogatko, et al.. (2004). Fibroblast activation protein and focal adhesion kinase: novel stromal therapeutic targets in pancreatic adenocarcinoma. Journal of Clinical Oncology. 22(14_suppl). 4094–4094. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nhu Le Breakdown of academic impact, for papers by Willa Shi Breakdown of academic impact, for papers by Cyril Abdeddaim Breakdown of academic impact, for papers by Yu Ohkubo Breakdown of academic impact, for papers by Zijun Zhen Breakdown of academic impact, for papers by François Casteillo Breakdown of academic impact, for papers by Ajit Paintal Breakdown of academic impact, for papers by Hari A. Deshpande Breakdown of academic impact, for papers by Christian Lussier Breakdown of academic impact, for papers by Paloma Martín-Martorell
Rankless by CCL
2026